Purpose: To evaluate the efficacy and complications of heavy silicone oil (Densiron 68) in primary inferiorly located retinal detachment. Methods: Sixty-seven eyes of patients aged 24–79 years with inferior primary rhegmatogenous retinal detachment with/without proliferative vitreoretinopathy grades C and lower were included in the study. The mean duration of the Densiron endotamponade was 87 days (range, 60–180 days), with a mean follow-up after removal of 110 ± 41 days. Results: Anatomical success was achieved in 64 of 67 eyes with completed follow-up. The mean visual acuity was changed significantly (p < 0.05). Partial superior redetachment occurred in 3 cases during endotamponade. No redetachment occurred after removal of the silicone oil. Postoperative best corrected visual acuity was better than 20/40 in 43 of cases at the end of follow-up. The mean intraocular pressure was 19.2 mm Hg during endotamponade follow-up. Mild to moderate intraocular inflammation was detected in 7 eyes. In 6 cases, adherence of residual bubble or bubbles was present after removal of the heavy silicone oil. Other complications, like elevated intraocular pressure (n = 6), emulsification (n = 8), temporary lens opacities (n = 14) or early cataract (n = 9), were detected after the operation. Conclusion: Long-term endotamponade with Densiron in inferior retinal detachment appears to be a safe and useful option.

Keywords:
Rhegmatogenous retinal detachment, Densiron, heavy silicone oil, Retina
1.
Rizzo S, Genovesi Ebert F, Vento A, Cresti F, Di Bartolo E, Belting C: A new silicone oil (HWS 46-3000) used as a prolonged internal tamponade agent in complicated vitreoretinal surgery. Retina 2007;27:613–620.
2.
Peyman GA, Schulmann JA, Sulivan B: Perfluorocarbon liquids in opthalmology. Surv Ophthalmol 1995;39:375–395.
3.
Machemer R, Aaberg TM, Freeman HMK, et al: An updated classification of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol 1991;112:159–165.
4.
Joussen AM, Kirchoff B, Schrage N, Ocklenburg C, Hilgers RD: Heavy silicone oil versus standard silicone oil as vitreous tamponade in inferior PVR (HSO Study): design issues and implications. Acta Ohthalmol Scand 2007;85:623–630.
5.
Sandner D, Engelmann K: First experiences with high density silicone oil (Densiron) as an intraocular tamponade in complex retinal detachment. Graefes Arch Clin Exp Ophthalmol 2006;244:609–619.
6.
Herbrig E, Sandner D, Engelmann K: Anatomical and functional results of endotamponade with heavy silicone oil – Densiron 68 – in complicated retinal detachment. Ophthalmic Res 2007;39:198–206.
7.
Wetterqvist C, Wong D, Williams R, et al: Tamponade efficiency of perfluorohexyloctane and silicone oil solutions in a model eye chamber. Br J Ophthalmol 2004;88:692–696.
8.
Lappas A, Kirchhof B, Konen W: Effects of the long term tamponade with Densiron on the lens. Klin Monatsbl Augenheilkd 2007;224:434–437.
9.
Quiram PA, Gonzales CR, Hu W, Gupta A, Yoshizumi MO, Kreiger AE, Schwartz SD: Outcomes of vitrectomy with inferior retinectomy in patients with recurrent rhegmatogenous retinal detachments and proliferative vitreoretinopathy. Ophthalmology 2006;113:2041–2047.
10.
Eckardt C, Eckardt U, Conrad HG: Macular rotation with and without counter rotation of the globe in patients with age related macular degeneration. Graefes Arch Clin Exp Ophthalmol 1999;237:313–325.
11.
Jonas JB, Knorr HL, Rank RM, Budde WM: Retinal redetachment after removal of intraocular silicone oil tamponade. Br J Ophthalmol 2001;85:1203–1207.
12.
Flaxel CJ, Mitchell SM, Aylward GW: Visual outcome after silicone oil removal and recurrent retinal detachment repair. Eye 2000;14:834–838.
13.
Abu El Asrar AM, Al Bishi SM, Kangave D: Outcome of temporary silicone oil tamponade in complex rhegmatogenous retinal detachment. Eur J Ophthalmol 2003;13:474–481.
14.
Bottoni F, Arpa P, Vinciguerra P, et al: Combined silicone and fluorosilicone oil tamponade (double filling) in the management of complicated retinal detachment. Ophthalomologica 2000;204:77–81.
15.
Tanji TM, Peyman GA, Nehta NJ, et al: Perfluoroperhydrophenantrene (Vitreon) as a short-term vitreous substitute after complex vitreoretinal surgery. Ophthalmic Surg 1993;24:681–685.
16.
Wong D, Van Meurs JC, Stappler T, et al: A pilot study on the use of a perfluorohexyloctane silicone oil solution as a heavier than water internal tamponade agent. Br J Ophthalmol 2005;89:662–665.
17.
Wolf S, Schön V, Meier P, Wiedamann P: Silicone oil RMN3 mixture (heavy silicone oil) as internal tamponade for complicated retinal detachment. Retina 2003;23:335–342.
18.
Theelen T, Tilanus MA, Klevering BJ: Intraocular inflammation following endotamponade with high density silicone oil. Graefes Arch Clin Exp Ophthalmol 2004:242:617–620.
19.
Rizzo S, Genovesi Ebert F, Belting C: The combined use of perfluorohexyloctane (F6H8) tamponade in the treatment of severe retinal detachment. Graefes Arch Clin Exp Ophthalmol 2006;244:709–716.
20.
Kaynak S, Oner HF, Koçak N, Lebe B: Secondary proliferations in heavy silicone oil endotamponade. Retin Cases Brief Rep 2007;1:217–219.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.